Neurocrine Biosciences Announces Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia Post author:Sam Post published:March 20, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like BioTelemetry Reaches Key Milestone In Tender Offer For LifeWatch Corp June 8, 2017 Apotex CEO Abruptly Resigns Amid Allegations of Trade Secret Leaks January 28, 2018 <b>Harmony Biosciences</b> Gains U.S. Rights to Pitolisant, Raises $270 Million October 5, 2017